Dual GIP/GLP-1 · SURMOUNT Trials · FDA Approved

Tirzepatide Results: 20.9% Body Weight Reduction

✅ FDA Approved

Last updated: April 2026

Tirzepatide (Mounjaro/Zepbound) isn't just another GLP-1 drug — it hits two receptors simultaneously. SURMOUNT-1 showed 20.9% average body weight reduction at 15mg over 72 weeks. Here's the full clinical picture.

20.9%
Peak Weight Loss
SURMOUNT-1, 15mg, 72 weeks
91%
Lost 5%+ Body Weight
At 15mg dose, SURMOUNT-1
Dual
GIP + GLP-1 Agonism
Unique vs semaglutide (GLP-1 only)
📋 On this page
  1. Why Tirzepatide Works Better Than GLP-1 Alone
  2. Weight Loss Results by Dose
  3. How Many People Hit Each Milestone?
  4. Tirzepatide vs Semaglutide
  5. Key Takeaways
  6. Explore More
  7. 🛒 Recommended Products
  8. 🔬 Research-Grade Peptides
  9. 🛒 Recommended Products
  10. 📚 Related Resources

Why Tirzepatide Works Better Than GLP-1 Alone

Semaglutide is GLP-1 only. Tirzepatide also activates GIP receptors — and the combination appears to be synergistic rather than merely additive.

🎯
GIP Receptor Agonism

GIP (glucose-dependent insulinotropic polypeptide) was historically considered "incretinomimetic" in diabetes. In obesity, GIP receptor activation in fat tissue and the CNS appears to amplify the satiety and metabolic effects of GLP-1. This is tirzepatide's edge — GIP sensitizes the GLP-1 pathway.

🧠
Central Satiety Enhancement

Both GIP and GLP-1 receptors are expressed in brain regions controlling appetite (hypothalamus, area postrema). Tirzepatide hits both simultaneously, producing stronger and more sustained satiety signals. Users typically report significant reduction in food reward and appetite compared to baseline.

📉
Insulin Sensitivity Improvement

Tirzepatide improves insulin sensitivity independent of weight loss. In T2D trials (SURPASS program), it achieved excellent glycemic control (HbA1c reduction 1.5-2.1%). This metabolic improvement may also contribute to fat loss by reducing insulin-driven fat storage.

🔥
Preservation of Lean Mass

Both STEP (semaglutide) and SURMOUNT trials showed a significant portion of weight loss comes from lean mass (muscle). Tirzepatide users lose roughly 25-35% lean mass alongside fat. This is an area of active research — pairing GLP-1 drugs with resistance training and adequate protein is strongly recommended.

Weight Loss Results by Dose

SURMOUNT-1 (N=2,539) compared tirzepatide 5mg, 10mg, and 15mg vs placebo over 72 weeks in adults with obesity (BMI ≥30 or ≥27 with comorbidity).

Tirzepatide 15mg — Peak Dose
SURMOUNT-1 primary endpoint, 72 weeks
-20.9%
Tirzepatide 10mg
SURMOUNT-1, 72 weeks
-19.5%
Tirzepatide 5mg
SURMOUNT-1, 72 weeks
-15.0%
Semaglutide 2.4mg (STEP-1 comparison)
Historical comparator — different trial, different population
-14.9%
Placebo
SURMOUNT-1 control arm
-3.1%

⚠️ Cross-trial comparison caveat: Semaglutide and tirzepatide data come from different trials with different populations. SURMOUNT-5 directly compared them head-to-head (tirzepatide won by ~47% more weight loss).

How Many People Hit Each Milestone?

SURMOUNT-1 at 15mg — what percentage of participants lost ≥X% of body weight:

Lost ≥5% body weight
Clinical benchmark for meaningful weight loss
91%
Lost ≥10% body weight
Sufficient for metabolic disease improvement
79%
Lost ≥15% body weight
Pre-bariatric surgery equivalent territory
68%
Lost ≥20% body weight
Results approaching bariatric surgery outcomes
57%
Lost ≥25% body weight
Exceptional response — roughly 1 in 3 participants
36%

Tirzepatide vs Semaglutide

SURMOUNT-5 directly compared them — the first head-to-head trial between the two leading GLP-1-class drugs.

Tirzepatide
20.9%
SURMOUNT-1 (15mg, 72 wks)
  • Dual GIP + GLP-1 mechanism
  • Weekly subcutaneous injection
  • Mounjaro (T2D) / Zepbound (obesity)
  • Better insulin sensitivity improvement
  • ~47% more weight loss vs semaglutide (SURMOUNT-5)
Semaglutide
14.9%
STEP-1 (2.4mg, 68 wks)
  • GLP-1 only mechanism
  • Weekly subcutaneous injection
  • Ozempic (T2D) / Wegovy (obesity)
  • Longer track record / more data
  • Also available as oral Rybelsus (different dose)

Key Takeaways

✅ What We Know
  • 20.9% avg weight loss at 15mg — largest in any GLP-1 trial at the time
  • 91% of patients lose ≥5% body weight (vs ~70% with semaglutide)
  • SURMOUNT-5 shows ~47% more weight loss vs semaglutide directly
  • Significantly improves insulin resistance and HbA1c
  • FDA approved for obesity (Zepbound) and T2D (Mounjaro)
⚠️ What to Keep In Mind
  • Weight regains when stopped — this is a chronic treatment
  • ~25-35% of weight lost is lean mass — resistance train and eat protein
  • GI side effects (nausea, vomiting) — dose titration helps
  • Cost without insurance: $1,000-1,400/month
  • Retatrutide trial data is beating these numbers — next generation incoming

🔬 Research-Grade Peptides

Swiss Chems

Third-party HPLC tested with published COAs. One of the most established research peptide vendors.

Browse Swiss Chems Peptides →

Affiliate link — supports HighPeptides at no extra cost

⚠️ Medical Disclaimer

Educational content only. Clinical trial data from SURMOUNT-1 (NCT04184622) published in NEJM, 2022. Individual results vary. Not medical advice. Consult a physician before starting tirzepatide or any GLP-1 medication.

Relevant supplies for GLP-1 weight loss.

⚖️ Smart Scale Track weight loss progress 📏 Body Measuring Tape Track inches lost 📓 Food Journal Track meals and progress 💉 Insulin Syringes For subcutaneous injection

Affiliate links help support HighPeptides at no extra cost to you.

⚕️ Disclaimer

This page is for educational and informational purposes only. It is not medical advice. Always consult with a qualified healthcare provider before starting any supplement or medication. Data sourced from published peer-reviewed research. HighPeptides may receive affiliate compensation from linked vendors.